There is now mounting evidence that certain receptor tyrosine kinases, including PDGFR and VEGFR/KDR, are promising targets for development of anti-fibrotic strategies. Both the PDGF and VEGF signaling pathways are activated in fibrotic development. Chronic kidney disease occurs when one suffers from gradual and usually permanent loss of kidney function over time, driven by tissue fibrosis. Scleroderma, also known as systemic sclerosis (SSc), is an autoimmune connective tissue disorder characterized by abnormal thickening and formation of scar tissue (fibrosis) in the skin, lung, gastrointestinal tract, heart and kidneys. Excessive extracellular matrix (ECM) protein (principally collagen) deposition in the skin and lung is a hallmark of scleroderma. Angion is currently developing inhibitors that target both PDGF and VEGF receptors, which may be therapeutic with respect to chronic kidney disease and scleroderma.
  |
|
|
   |
       |